Low levels of caspase-9 protein in primary tumour could therefore identify patients that are most likely to benefit from non-caspase-9 dependent treatments, such as death receptor (DR)-mediated apoptosis through caspase-8 cleavage and induction of the non-mitochondrial apoptotic pathway [51], [52]. Here, CASP9 is linked to neoplasm.